Back to News
Market Impact: 0.2
GSK to nearly double cancer drugs in trials, WSJ reports
Source: reuters.com
Healthcare & BiotechCorporate Guidance & Outlook
GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, according to a Wall Street Journal report citing an interview with a scientist. The report provides no absolute medicine count or further details on the candidates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
GSK0.55
More News
- Wednesday's big stock stories: What’s likely to move the market in the next trading session
- Tech's relief rally extends as attention turns to tough decisions for the Fed
- Stifel’s surprise gaming pick leads a sector bracing for a choppy earnings season
- Boeing shares slide on a disappointing cash flow update. Why this dip is buyable
- AI debt fears ease ahead of Oracle, Alphabet and Amazon updates. Here's what to watch.
- Airlines are trading nearly 23% higher ticket prices for emptier planes as jet fuel prices spike over 90% from the Iran War’s fuel squeeze